LBPS 02-60 COMBINED ANTIHYPERTENSIVE THERAPY IN THE TREATMENT OF HYPERTENSION IN THE METABOLIC SYNDROME

    loading  Checking for direct PDF access through Ovid

Abstract

Objective:

Antihypertensive therapy in the metabolic syndrome must possess contested impact on finite cardiovascular points, have no adverse metabolic effects, affect the pathogenetic components hypertension and insulin resistance have a variety of protective effects with beneficial effects on endothelial function, platelet-vascular hemostasis and fibrinolysis. The purpose of our work to study the efficacy of combination therapy with antihypertensive drugs from the groups blockers angiotensin receptor AT1 (valsartan) and I1 is agonist imidazoline receptors (moxonidine) in patients the metabolic syndrome with hypertension.

Design and Method:

The study involved 40 patients with hypertension in the framework of the metabolic syndrome. Criteria for inclusion in the study: systolic blood pressure (SBP) ≥140; diastolic blood pressure (DBP) ≥90 mmHg; abdominal obesity; the presence of dyslipidemia; impaired glucose tolerance (glucose in plasma 2 hours after glucose load and in the range ≥7,8 ≤11,1 mmol/l).

Results:

So patients treated with a combination of valsartan and moxonidine target blood pressure (140/80 mmHg) reached 34 patients (85%). In 6 patients (15%) failed to achieve target blood pressure, although the decrease was recorded as the systolic and diastolic blood pressure. At baseline, the mean SBP was 162.5 ± 1.53, DBP average 92.67 ± 1.37 mmHg. After 2 weeks, SBP and DBP, respectively, decreased by 16.81% and 12.22%. SBP was 135.2 ± 2.31, DBP 81.33 ± 1.22 mmHg. As a result of treatment, the mean diurnal SBP decreased by 6.2% and amounted to 133.5 ± 1.79 mmHg, mean daily DBP decreased by 4.62% and amounted to 84.55 ± 1.04 mmHg the average daytime SBP and DBP decreased by 5.19% and 4.3% respectively. SBP was 133.3 ± 1.39, DBP 84.58 ± 1.04 mmHg.

Conclusions:

Thus, recommended by us a rational drug combination of valsartan and moxonidine allowed us to reach target blood pressure and normalize circadian rhythm of blood pressure, which in turn should lead to a significant reduction in the risk of cardiovascular complications and improve quality of life in patients.

Related Topics

    loading  Loading Related Articles